Information  X 
Enter a valid email address

RedxPhar Ord 1p (REDX)

Date Time Source Announcement
06 Dec 2021 7:00 am
RNS
Redx and Caris Life Sciences Announce Partnership
30 Nov 2021 7:00 am
RNS
Redx to Participate at Piper Sandler Conference
17 Nov 2021 7:00 am
RNS
Redx to Present at Jefferies London Conference
15 Nov 2021 7:00 am
RNS
First Patient Dosed in Phase 2 Trial of RXC004
01 Nov 2021 7:00 am
RNS
Appointment of Non-Executive Chair
11 Oct 2021 7:00 am
RNS
R&D Day and New Clinical Data for ROCK2 Inhibitor
05 Oct 2021 7:00 am
RNS
Redx to host Virtual R&D Day on 11 October 2021
27 Sep 2021 8:00 am
RNS
Exercise of Options and Total Voting Rights
20 Sep 2021 4:59 pm
RNS
Redx Presents Encouraging Phase 1 Data for RXC004
17 Sep 2021 11:06 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
16 Sep 2021 12:16 pm
RNS
Price Monitoring Extension
  12:15 pm
RNS
Second Price Monitoring Extn
  12:12 pm
RNS
Second Price Monitoring Extn
  12:08 pm
RNS
Price Monitoring Extension
14 Sep 2021 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
  11:05 am
RNS
Second Price Monitoring Extn
  11:00 am
RNS
Price Monitoring Extension
13 Sep 2021 7:00 am
RNS
RXC004 Phase 1 data to be presented at ESMO 2021
06 Sep 2021 9:05 am
RNS
Second Price Monitoring Extn
  9:00 am
RNS
Price Monitoring Extension
02 Sep 2021 7:00 am
RNS
Milestone Payment from Jazz Pharmaceuticals
27 Jul 2021 7:00 am
RNS
Redx Announces Phase 2 Dose Selection of RXC004
08 Jul 2021 1:43 pm
RNS
Exercise of Options and Total Voting Rights
01 Jul 2021 11:08 am
RNS
New Grant of Options and Director/PDMR Dealing
17 Jun 2021 7:00 am
RNS
Redx Receives Milestone Payment for RXC006
07 Jun 2021 7:00 am
RNS
Interim results for the six months ended 31 March
04 Jun 2021 7:00 am
RNS
Change of Auditor
03 Jun 2021 7:00 am
RNS
First Subject Dosed in Phase 1 Study with RXC007
01 Jun 2021 7:00 am
RNS
Directorate Change
24 May 2021 7:00 am
RNS
Notice of Interim Results
19 May 2021 7:00 am
RNS
Appointment of Non-Executive Director
05 May 2021 7:00 am
RNS
Appointment of Peter Collum as CFO
30 Apr 2021 9:00 am
RNS
Confirmation of post offer intention statements
28 Apr 2021 7:00 am
RNS
Dosing of first patients with RXC004 and Anti-PD1
29 Mar 2021 9:00 am
RNS
Redx to present at AACR
15 Mar 2021 7:00 am
RNS
Appointment of Joint Broker
02 Mar 2021 12:38 pm
RNS
Result of AGM and Directorate change
01 Mar 2021 9:57 am
RNS
New Grant of Options
25 Feb 2021 7:00 am
RNS
Presentation at Cowen Healthcare Conference
05 Feb 2021 5:23 pm
RNS
Notice of AGM
27 Jan 2021 7:00 am
RNS
Final Results for the Year Ended 30 September 2020
14 Jan 2021 7:00 am
RNS
Notice of Preliminary Results
29 Dec 2020 7:00 am
RNS
TR-1: Notification of major holdings
23 Dec 2020 9:00 am
RNS
Share Purchases by Directors
22 Dec 2020 5:13 pm
RNS
TR-1: Notification of major holdings
  8:30 am
RNS
Admission of Placing
21 Dec 2020 12:26 pm
RNS
Results of Open Offer and General Meeting
02 Dec 2020 7:10 am
RNS
New Grant of Options
  7:00 am
RNS
Placing and Open Offer Announcement
27 Oct 2020 7:00 am
RNS
Appointment of Chief Medical Officer
09 Sep 2020 7:00 am
RNS
Research collaboration with Jazz Pharmaceuticals
03 Sep 2020 3:00 pm
RNS
TR-1: Notification of major holdings
17 Aug 2020 2:05 pm
RNS
Second Price Monitoring Extn
  2:00 pm
RNS
Price Monitoring Extension
05 Aug 2020 7:00 am
RNS
Appointment of NED and changes to Board committees
04 Aug 2020 7:37 am
RNS
Out licensing agreement with AstraZeneca
20 Jul 2020 11:35 am
RNS
Result of General Meeting
02 Jul 2020 2:05 pm
RNS
Second Price Monitoring Extn

a d v e r t i s e m e n t